Gsk Pharma India Profile
Key Indicators
- Authorised Capital ₹ 12.80 Cr
- Paid Up Capital ₹ 7.68 Cr
- Company Age 24 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 14.33%
- Profit Growth 12.65%
- Ebitda 19.11%
- Net Worth 34.96%
- Total Assets 170.67%
About Gsk Pharma India
Gsk Pharma India Private Limited (GPIPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 02 June 2000 and has a history of 24 years and eight months. Its registered office is in Mumbai, Maharashtra, India.
The Corporate was formerly known as Stiefel India Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 12.80 Cr and a paid-up capital of Rs 7.68 Cr, as per Ministry of Corporate Affairs (MCA) records.
Ajay Nadkarni and Ayush Kumar serve as directors at the Company.
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24239MH2000PTC126937
- Company No.
126937
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 Jun 2000
- Date of AGM
25 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
What products or services does Gsk Pharma India Private Limited offer?
Gsk Pharma India Private Limited offers a wide range of products and services, including Skin Care, Acne Care, Sunscreen Products, Health Conditions, Piles, Fissures & Fistula, Bath Essentials.
Who are the key members and board of directors at Gsk Pharma India?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ajay Nadkarni  | Director | 03-Jan-2011 | Current |
| Ayush Kumar | Director | 17-Jan-2024 | Current |
Financial Performance of Gsk Pharma India.
Gsk Pharma India Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 14.33% increase. The company also saw a substantial improvement in profitability, with a 12.65% increase in profit. The company's net worth Soared by an impressive increase of 34.96%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Gsk Pharma India?
In 2023, Gsk Pharma India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Biddle Sawyer LimitedAjay Nadkarni is a mutual person
Gsk India Global Services Private LimitedAjay Nadkarni is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Gsk Pharma India?
Unlock and access historical data on people associated with Gsk Pharma India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Gsk Pharma India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Gsk Pharma India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
